Saad Abdulrahman Hussain, İhab İbrahim ALKHALİFA, NİZAR ABDULLATEEF JASSİM, Saad Abdulrahman HUSSAİN, İhab İbrahim ALKHALİFA, Nizzar Abdullateef JASSİM

Adjuvant Use of Melatonin with Fluoxetine for Management of Fibromyalgia

Fibromyalgia (FMS) is a chronic musculoskeletal disorder characterized by generalized muscular pain and tenderness at specific anatomical sites. Although melatonin was effective in treating the pain associated with this syndrome, no defined clinical evidence supports this claim. The present study was designed to evaluate the clinical significance of using melatonin, alone or in combination with fluoxetine in FMS. A double-blind clinical study was conducted on 45 patients with FMS randomized into 4 groups; group A, treated with fluoxetine 20mg/day alone; group B, treated with melatonin 5mg alone; group C, treated with combination of fluoxetine 20 mg+3 mg melatonin; group D treated with combination of fluoxetine 20 mg+5 mg melatonin. Both fluoxetine and melatonin were given once daily in the morning and night time respectively for 8 weeks. Each patient clinically evaluated using Fibromyalgia Impact Questionnaire (FIQ). Serum levels of serotonin, malondialehyde and nitric oxide were also evaluated. Using melatonin (3 and 5mg/day) in combination with 20mg/day fluoxetine significantly decreased total FIQ score values; the combination therapy significantly decreased serum serotonin level associated with reduction in the oxidative stress parameters (MDA and NO). In conclusion, adjuvant use of melatonin with fluoxetine improves the biochemical and clinical parameters of FMS patients.

Keywords:

Fibromyalgia; Oxidative Stress; Serotonin; MDA; Nitric oxide,

PDF

___

Koopman WJ, Boulware DW, Gustavo R, Heudebert GR. Fibromyalgia; Clinical Primer of Rheumatology, Lippincott Williams and Wilkins, Philadelphia; 2003; 226-35.
White KP, Speechley M, Harth M. The London FMS Epidimiology Study: The prevalence of FMS in London. J Rheumatol 1999; 26:1570-6.
Erin L, Rose RL, Allghanbari V. A review of fibromyalgia and its treatment. Drug Topics 2005; 11:38-48.
Rao SG, Gendreau JF, Kranzler JD. Understanding the fibromyalgia syndrome. Psychopharmacol Bull 2008; 40:24-56.
Goldenberg L. Fibromyalgia and related syndromes, Choochberg M, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, (eds); Textbook of Practical Rheumatology, (3 rd ed), 2004:255-66.
Elide PK, Hole K. Interaction between serotonin and substance P in the regulation of nociception. Brain Res 1991; 550:225-30.
Russell JM, Michalek JE, Vipraio GA. Platelets 3H-impramine uptake receptor density and serum serotonin levels in patients with FMS. J Rheumatol 1992; 19:104-9.
Russell IJ. The neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskel Pain 1996; 4:61-92.
Ozgocmen S, Ozyurt H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2005; 10:1-6.
Mclver KL, Evans C. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain 2006; 120:161-9.
Mense S. Neurobiological basis of muscle pain. Schmerz 1999; 13:3-17.
Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome, and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypoth 2001; 57:139-45.
Zhang H, Akbar M, Kim HY. Melatonin: an endogenous negative modulator of 1 2lipoxygenase in the rat pineal gland. Biochem J 1999; 344:487-93.
Storr M, Koppitz P, Sibaev A. Melatonin reduces non- adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vivo. J Pineal Res 2002; 33:101-8.
Vural H, Sabuncu T, Arslan SO, Aksoy N. Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats. J Pineal Res 2001; 31:193-8.
Cuzzocrea S, Constantino G, Mazzon E, Caputi AP. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J Pineal Res 1999; 27:9-14.
Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Age Develop 2002; 123:1007-19. Cuzzocrea S, Tan DX, Constantino G, Mazzon E, Caputi AP, Reiter RJ. The protective role of endogenous melatonin in carrageenan-induced pleurisy in rat. FASEB J 1999; 13:1930-8.
Meenan RF, German PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum 1980; 23:146-52.
Hunter MI, Nlemadim BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10:1645-52.
Mirenda KM, Espey MG, Wink DA. Rapid and simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5:62-71.
Iceta R, Mesonero JE, Alcalde AI. E ﬀect of long-term ﬂuoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci 2007; 80:1517-24.
White KP, Nielson WR, Ostbye T, Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within group comparison in a community cohort of adult with chronic widespread pain. Arthritis Rheum 2002; 47:260-5.
Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112:191-7.
Wolf F, Cathey MA, Hawley DJ. A double-blind placebo, controlled trail of fluoxetine in FMS. Scand J Rheumatol 1994; 23:255-9.
Citera G, Arias M, Maldonado-Cocca JA, Lazaro MA. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000; 19:9-13.
Reiter RJ, Acuna-Castroviejio D, Tan DX. Melatonin therapy in Fibromyalgia. J Pineal Res 2006; 40:98-9.
Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002; 28:181-99.
John H, Juhi DO. Fibromyalgia and the serotonin pathway. Altern Med Rev 1998; 3:367
Russell IJ, Vipraio GA, Lopez YG. Serum serotonin (5HT) in fibromyalgia syndrome (FMS), rheumatoid arthritis (RA), osteoarthritis (OA) and normal controls. Arthritis Rheum 1993; 36:208-22.
Hrycaj P, Starz T, Muller W. Platelet 3H-impramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1993; 80:1986
Russell IJ. Neurohormonal aspects of fibromyalgia syndrome. Rheum Dis Clin North Am 1989; 15:149-68.
Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology 1992; 17:593-8.
Alveraz JC, Nathalie G, Alain F, Anne G. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor of antidepressant response? Psychopharmacology 1999; 143:97-101.
Ortiz J, Artigas F, Gelpi E. Serotoninergic status in human blood. Life Sci 1988; 43:983
Montgomery SA. Clinical aspects of onset of action of anti-depressant efficacy. Biol Psychiatr 1991; 29:114S.
Jeschonneck M, Grohmann G, Hein G, Spartt H. Abnormal microcirculation and temperature in skin above tender points in patients with FMS. Rheumatology 2000; 39:917-21.
Yunus MB, Kalyan RU, Kalyan RK, Masi AT. Pathologic change in muscle in primary FMS. Am J Med 1986; 81:38-42.
Ozogocmen S, Ozyrut H, Sogut S. Antioxidant status, lipid peroxidation, and Nitric oxide in FMS: etiologic and therapeutic concerns. Rheumatol Int 2006; 26:598-603.
Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with FMS. Redox Rep 2006; 11:131-5.
Hausladen A, Stamler JS. Nitrostative stress. Methods Enzymol 1999; 300:389-5.
Akkus S, Naziroglu M, Eris S. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Func 2009; 18:181-5.
Sendur OF, Turan Y, Tastaban E. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int 2009; 29(6):629-33.
Bennett R. Fibromyalgia: present to future. Curr Rheumatol Rep 2005; 7(5):371-6.
Eisinger J, Zakarian H, Pouly F, Plantamura A, Ayavou T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnesium Res 1994; 7:285-8.
Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskel Pain 1997; 5(4):5-16.
Leon J, Macias M, Escames G, Camacho E, Khaldy H, Espinosa A, Gallo MA, Castroviejo D. Structure-related inhibition of calmodulin-dependent nNOS activity by melatonin and synthetic kynurenines. Mol Pharmacol 2000; 58:966-75.